drugset / Trial / NCT05857358
Safety and Potential Effect of Innovative Cell-based Therapy Using Adipose-derived Stromal Vascular Fraction in Patients With Autoimmune Xerostomia
NaSingle-groupOpen-labelTreatment
Summary
The main objective of this study is to evaluate the tolerance and safety of autologous adipose-derived stromal vascular fraction injected in accessory salivary glands for treatment of autoimmune xerostomia in terms of adverse reactions through day 14 (D14).
Timeline
- Start
- 2024-01
- Primary completion
- 2026-02
- Completion
- 2027-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AD-SVF | Cell therapy | 3 ml | Other |
| Subject | AD-SVF | Cell therapy | 30 cells | Other |
Indications
No indication recorded.